Economic Burden of Typhoid Antibiotic Resistance

General Studies Paper II: Health, Government Policies & Interventions

Why in News?

Antibiotic-resistant typhoid accounted for 87% of India’s total INR 123 billion typhoid economic burden in 2023, according to a study published in The Lancet Regional Health Southeast Asia.

Highlights of Lancet Regional Health Southeast Asia Study

Data Analysis: Researchers used a nationally representative dataset on typhoid epidemiology, care‑seeking behaviour, clinical outcomes, and direct/indirect costs covering both hospitalised and non‑hospitalised patients.
Economic Burden: The study estimated that typhoid fever caused a total economic burden of approximately ₹12,300 crore (₹123 billion) in India in 2023, with antibiotic‑resistant infections accounting for 87 % of this cost — showing how much resistance drives expenses rather than the disease alone.
Primary Driver: Antibiotic‑resistant infections — especially those resistant to fluoroquinolone antibiotics — were identified as the primary driver of the economic burden, disproportionately increasing treatment difficulty, duration, and cost.
- The analysis highlighted that resistance to fluoroquinolones — once effective first‑line drugs for severe typhoid — now contributes to the majority of costs, as therapy failures and prolonged illness drive up both direct and indirect expenses.
Age‑Specific Burden: The study found that children aged under 10 years bore more than half of the total economic burden, indicating significant vulnerabilities among young children and emphasizing the need for child‑focused prevention and care strategies.
Household Financial Strain: Analysis showed that households bore 91 % of all typhoid treatment costs out‑of‑pocket, pushing many families into financial distress, with about 70,000 families facing “catastrophic” health expenditure that threatened their ability to meet basic needs.
Geographic Distribution: The report identified key high‑burden states — Maharashtra, Uttar Pradesh, Andhra Pradesh (including Telangana), Tamil Nadu, and West Bengal — which together accounted for over half (51 %) of the national typhoid economic burden, indicating policy priorities for targeted interventions.
Policy Implications: The study’s findings support accelerating the introduction of the typhoid conjugate vaccine (TCV) into India’s national immunisation schedule, along with strengthening antibiotic resistance surveillance, stewardship, and tailored national health financing policies to alleviate both the health and economic impacts.

What is Typhoid?

About: Typhoid fever is a life‑threatening systemic bacterial infection that primarily affects the intestinal tract and bloodstream, spreading throughout the body if untreated.
Causative Agent: The disease is caused specifically by the bacterium Salmonella Typhi, a human‑specific pathogen that does not naturally infect animals and lives only in humans.
Transmission: Transmission is faecal‑oral, meaning people get infected by consuming contaminated water or food that contains feces from infected individuals. Poor hygiene and sanitation make this spread common in areas without safe water.
Incubation Period: After exposure, symptoms typically appear 6–30 days later, most commonly around 10–14 days, as bacteria multiply within the body before causing noticeable illness.
Symptoms: The hallmark of typhoid includes prolonged high fever, fatigue, headache, abdominal pain, nausea, and either diarrhoea or constipation. Some patients may also show a rose‑colored skin rash (“rose spots”).
Effects: The infection can affect multiple organs beyond the gut. Severe cases may lead to liver inflammation, kidney problems, pneumonia or heart involvement, especially without timely treatment.
Chronic Carriers: Even after recovery, 2–5 % of patients may become chronic carriers, meaning they continue to shed bacteria in their stool and can unknowingly continue to spread the disease.
Diagnosis: Diagnosis is usually made through blood cultures, which detect the bacteria in the bloodstream. Stool culture and bone marrow culture are additional methods.
Treatment: Typhoid is treated with antibiotics that kill the bacteria.
- Prevention focuses on safe drinking water, good sanitation, proper hygiene, and typhoid vaccination.
- The typhoid conjugate vaccine (TCV) is recommended for routine use in endemic areas.

Antibiotic Resistance: Causes and Patterns

About: Antibiotic resistance occurs when bacteria change in ways that reduce or eliminate the effectiveness of antibiotics that once killed them or stopped their growth. These changes make treatments fail, prolong infections, and increase mortality.
Causes: Resistance can originate through natural genetic mutation or selection. When bacteria replicate, random genetic changes occasionally make some survive antibiotic exposure.
- Bacteria can acquire resistance genes from other bacteria through horizontal gene transfer (HGT) — including conjugation, transduction, and transformation.
Multidrug‑Resistant (MDR) Typhoid: MDR typhoid is defined as strains resistant to three historical first‑line antibiotics — chloramphenicol, ampicillin, and trimethoprim‑sulfamethoxazole.
- These strains emerged strongly in the 1970s and 1980s and spread widely in South Asia and beyond.
Extensively Drug‑Resistant (XDR) Typhoid: XDR typhoid goes further than MDR: these strains are resistant to first‑line antibiotics, fluoroquinolones, and third‑generation cephalosporins, leaving only limited options like azithromycin or carbapenems.
- XDR outbreaks first appeared in Pakistan in 2016 and have been identified globally.
Impact: Resistant strains lead to treatment failure, longer illness, increased risk of complications, and higher healthcare costs because standard antibiotics fail and clinicians must resort to more expensive or injectable drugs.
- Factors like misuse and overuse of antibiotics, self‑medication, inadequate diagnostics, and poor sanitation contribute to the emergence and spread of resistant typhoid strains.

Government Policies to Combat Antibiotic‑Resistant Typhoid

National Action Plan on Antimicrobial Resistance (2025–29): India’s updated National Action Plan on Antimicrobial Resistance (NAP‑AMR 2.0) adopts a One Health approach focusing on surveillance, antibiotic stewardship, infection control, and public awareness to slow antimicrobial resistance (AMR) including resistant Salmonella Typhi.
- Originally launched in 2011 and reinforced through subsequent frameworks, national AMR containment policy and Schedule H1 regulation restrict over‑the‑counter sale of critical antibiotics, helping reduce inappropriate antibiotic use that accelerates resistant typhoid.
National Treatment Guidelines: The National Centre for Disease Control (NCDC) issues standard treatment guidelines which include appropriate antibiotic choices (e.g., azithromycin, ceftriaxone) for uncomplicated and complicated typhoid, promoting rational antibiotic use.
Expanded Programme on Immunisation (EPI): India’s immunisation framework has introduced typhoid vaccines in select campaigns (for example, Navi Mumbai TCV campaign achieving ~71% coverage) showing feasibility of vaccine‑led prevention strategies in high‑burden communities.
NTAGI Recommendation: The National Technical Advisory Group on Immunisation (NTAGI) recommended the inclusion of typhoid conjugate vaccine (TCV) in the Universal Immunisation Programme to prevent disease and reduce antibiotic use, though full nationwide rollout is still under consideration.
Surveillance: Under Integrated Disease Surveillance Programme (IDSP) and Surveillance for Enteric Fever in India (SEFI), monitoring of typhoid incidence helps track trends and resistance patterns, guiding targeted interventions and policy decisions.
WASH Initiatives: Government programs like Swachh Bharat Mission and other WASH (Water, Sanitation and Hygiene) strategies aim to reduce faecal‑oral transmission of typhoid by improving access to clean water and sanitation facilities.
WHO Recommendation: The World Health Organization (WHO) recommends typhoid conjugate vaccines (TCVs) for routine use in endemic countries to prevent infections and curb antibiotic resistance; WHO prequalified TCVs in 2017, prioritising them for high‑burden settings.
Gavi: Gavi, the global public-private Vaccine Alliance (2000) supports countries to introduce TCV into routine immunisation with co‑financing and fully funded catch‑up campaigns (up to 15 years of age) to rapidly increase coverage and reduce disease burden.
- As of early 2026, Gavi has helped vaccinate over 1.2 billion children and averted more than 20.6 million future deaths.
- At the Global Vaccines Summit on June 4, 2020, hosted by the United Kingdom, India pledged USD 15 million as India’s contribution to Gavi for its 2021–2025 programme.